HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors
University of California San Diego · Washington University in St. Louis · +5 more institutions
Abstract
Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to be reported. Because large HIV-infected (HIV+) and uninfected (HIV-) groups have not been studied with similar methods in the pre-CART and CART eras, it is unclear whether CART has changed the prevalence, nature, and clinical correlates of HAND. We used comparable methods of subject screening and assessments to classify neurocognitive impairment (NCI) in large groups of HIV + and HIV - participants from the pre-CART era (1988-1995; N = 857) and CART era (2000-2007; N = 937). Impairment rate increased with successive…
Citation impact
- FWCI
- 22.65
- Percentile
- 100%
- References
- 43
Authors
28- FTfor the CHARTER and HNRC GroupsCorresponding
University of California San Diego
- RKRobert K. Heaton
University of California San Diego
- DFDonald Franklin
University of California San Diego
- RJRonald J. Ellis
University of California San Diego
- JAJ. Allen McCutchan
University of California San Diego
Topics & keywords
- Cart
- Neurocognitive
- Medicine
- Immunosuppression
- Antiretroviral therapy
- Internal medicine
- Disease
- Neurology
- Good health and well-being